Naibec Maintains Profit in Q2... "Expecting Growth in Overseas Exports"

Naivek announced on the 16th that its operating profit for the second quarter of this year recorded 280 million KRW, maintaining a profit for the second consecutive year. However, sales decreased by approximately 25.1% compared to the same period last year, recording 4.13 billion KRW due to delays in supplying products to Europe. Additionally, a net loss of 360 million KRW was recorded.

In Europe, the region with the largest sales scale, sales of the core implant material, bone regeneration biomaterial, temporarily decreased due to delays in supply caused by the 'MDR (Medical Device Regulation)' certification. However, since most of this is deferred demand expected to be recognized as supply volume in the second half of the year, the outlook for the second half and annual performance is positive.

Outside Europe, sales in other global countries such as the United States and China, as well as domestically, increased in the second quarter. In the United States, the establishment of a California corporation is underway, and preparations for direct entry are progressing smoothly. In addition to the sales channels of the current global first and second-ranked implant companies, new distribution channels based on its own brand will be secured to conduct direct sales in parallel.

In China, the company applied for product approval for 'GuidOss,' a core implant material, in May, and the review is ongoing. Clinical trials for the collagen composite material OCS-B collagen product are also being conducted. The company explained that it plans to expand sales in the Chinese implant market by building a diverse product lineup including the existing 'OCS-B.'

A Naivek representative said, "Sales in the European region temporarily decreased in the second quarter due to supply delays related to certification issues, but normalization is underway. In the United States, the establishment of the corporation and the setup of the sales organization will be completed soon, and full-scale efforts to secure sales channels will begin. In China, various negotiations are underway to expand existing distribution channels and volumes."

To proactively respond to the increasing global demand, Naivek has significantly expanded its production capacity by establishing a large-scale biomaterial Plant 2 in Jincheon, Chungbuk. The existing Plant 1 produced biomaterials worth up to 50 billion KRW annually, but with the construction of the new plant, production capacity has increased to up to 300 billion KRW annually. Naivek is currently undergoing the certification process for Good Manufacturing Practice (GMP) and plans to complete the certification by the end of this year and start full-scale operation.

This content was produced with the assistance of AI translation services.